Altamira Therapeutics Ltd

1
NAS:CYTO (Bermuda)  
$ 1.66 -0.17 (-9.29%) 11:09 PM EST
At Loss
Volume:
120.19K
Avg Vol (2M):
1.65M
Also Trade In:
Volume:
120.19K
At Loss
Avg Vol (2M):
1.65M

Business Description

Description
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.
Name Current Vs Industry Vs History
Cash-To-Debt 0.02
Equity-to-Asset -0.29
Debt-to-Equity -1.9
Debt-to-EBITDA -0.16
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -60.07
Distress
Grey
Safe
Beneish M-Score -11.25
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 15.4
3-Year EPS without NRI Growth Rate 13.7
3-Year FCF Growth Rate 46.6
Name Current Vs Industry Vs History
5-Day RSI 26.52
9-Day RSI 35.72
14-Day RSI 40.32
6-1 Month Momentum % -63.58
12-1 Month Momentum % -92.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.32
Quick Ratio 0.27
Cash Ratio 0.01
Days Inventory 111.57
Days Sales Outstanding 212.23
Days Payable 2539.37

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -78.9
Shareholder Yield % -208.49
Name Current Vs Industry Vs History
Gross Margin % -280.45
Operating Margin % -18128.57
Net Margin % -19288.72
FCF Margin % 323925
ROE % -1089.36
ROA % -235.33
ROIC % -176.01
ROC (Joel Greenblatt) % -5122.85
ROCE % -2594.97

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 1.91
EV-to-EBIT -1.12
EV-to-EBITDA -1.14
EV-to-Revenue -1952.5
EV-to-FCF -0.62
Earnings Yield (Greenblatt) % -89.29
FCF Yield % -348.4

Financials

CYTO's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CYTO

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Altamira Therapeutics Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) -0.004
EPS (TTM) ($) -27.44
Beta 2.42
Volatility % 204.61
14-Day RSI 40.32
14-Day ATR ($) 0.246088
20-Day SMA ($) 1.9445
12-1 Month Momentum % -92.35
52-Week Range ($) 1.61 - 29
Shares Outstanding (Mil) 2.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Altamira Therapeutics Ltd Filings

Filing Date Document Date Form
No Filing Data

Altamira Therapeutics Ltd Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Altamira Therapeutics Ltd Frequently Asked Questions

What is Altamira Therapeutics Ltd(CYTO)'s stock price today?
The current price of CYTO is $1.66. The 52 week high of CYTO is $29.00 and 52 week low is $1.61.
When is next earnings date of Altamira Therapeutics Ltd(CYTO)?
The next earnings date of Altamira Therapeutics Ltd(CYTO) is .
Does Altamira Therapeutics Ltd(CYTO) pay dividends? If so, how much?
Altamira Therapeutics Ltd(CYTO) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1